Posts in: melanoma testing

Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors

December 20, 2017

Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.

November 7, 2017

Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients